Results 121 to 130 of about 4,521,628 (366)

Pharmacoeconomic evaluation of treatments for Poly Cystic Ovarian Syndrome (PCOS)

open access: yesCost Effectiveness and Resource Allocation
Background Treatment cost and high prevalence of Poly Cystic Ovarian Syndrome (PCOS) is a very challenging issue globally. Due to this reason; current study was conducted to determine pharmaco-economy of conventional and non-conventional treatments for ...
Darakhshan Masroor   +4 more
doaj   +1 more source

EE31 Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis [PDF]

open access: bronze, 2023
Dominic Voehler   +5 more
openalex   +1 more source

Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology

open access: yesMolecular Oncology, EarlyView.
Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...
Marius Ilié   +13 more
wiley   +1 more source

Table_2_PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China.doc

open access: green, 2021
Qiao Liu (346535)   +7 more
openalex   +2 more sources

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

open access: yesCost Effectiveness and Resource Allocation, 2017
BackgroundIn Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorization in 2015 to protect, with only ...
F. Mennini   +8 more
semanticscholar   +1 more source

Cost Effectiveness Analysis Of Ticagrelor Versus Generic Clopidogrel In The Treatment Of Patients With Acute Coronary Syndrome In Spain [PDF]

open access: bronze, 2014
Margarita Capel   +4 more
openalex   +1 more source

Cost-effectiveness analysis and its application for policy evaluation for medicine or public health [PDF]

open access: yes
In comparison to the policy for other field, the policy for medicine and public health is to consider the value of life or the value of the quality of life. Quality of life is very well known as a concept of QOL.
Tamie Sugawara, Yasushi Ohkusa
core   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines

open access: yesClinicoEconomics and Outcomes Research, 2011
Giorgio L Colombo1,2, Vincenzo Colangeli3, Antonio Di Biagio4, Sergio Di Matteo2, Claudio Viscoli4, Pierluigi Viale31School of Pharmacy, University of Pavia, Pavia, Italy; 2SAVE - Studi Analisi Valutazioni Economiche, Milan, Italy; 3Clinica Malattie ...
Viale P   +5 more
doaj  

Home - About - Disclaimer - Privacy